SMARCA4 and neoplasm: Remarkably, combined SMARCA4/ERBB inhibition showed efficacy in delaying tumor growth, even in PDXs derived from tumors after several lines of treatment, supporting the potential of this combinatorial therapy as a therapeutic strategy for the treatment of SCLC.